3653 results for «358»
3653 results
Outcomes after novel transcatheter and surgical tricuspid valve interventions
21 Nov 2021 – From PCR London Valves 2021
Find out more about TRI-SCORE, a new risk score to predict in-hospital mortality after isolated tricuspid valve surgery, 30-day outcomes for transcatheter tricuspid repair from the TriBAND study, both the CLASP TR early feasibility and TRISCEND studies six-month results, and more in this PCR London Valves...
Emergent transcatheter therapy
21 Nov 2021 – From PCR London Valves 2021
This series of 3 videos presented during the PCR London Valves 2021 Congress allows you to appreciate an emergent mitral ViV implantation after a recent re-do bioprosthetic AVR, a cardiogenic shock after transfemoral mitral valve reconstruction, and MitraClip for torrential mitral regurgitation with Impella CP support.
Miscellaneous - Paravalvular leak closure, PFO closure and LAA occlusion
21 Nov 2021 – From PCR London Valves 2021
Want to know more about the impact of baseline PFO anatomy on residual right to left shunt after transcatheter closure, transcatheter closure of paravalvular leak, or even percutaneous mitral paravalvular leak closure using CT planning? This PCR London Valves 2021 session is for you!
Unusual situations in valvular interventions
21 Nov 2021 – From PCR London Valves 2021
Let's discover an electrosurgical removal of an entrapped central venous catheter, witness a coronary extra-adventitial hematoma complication of transcatheter tricuspid annuloplasty, and appreciate buddy balloon technique as bailout strategy during RVOT stent embolization, among others, in this special PCR London Valves 2021 session dedicated to unusual...
Transcatheter mitral, aortic and pulmonary valve implantation
21 Nov 2021 – From PCR London Valves 2021
Watch this series of videos from PCR London Valves 2021 to learn about acute heart failure hospitalizations following TAVI in the U.S., share a peripheral hospital's experiences with structural valve service modernization, enjoy percutaneous transseptal mitral valve implantation in Brazil, and more!
PCR London Valves 2021 Hotlines / Late-Breaking Trials: bRIGHT, EXPAND, CHOICE-MI
21 Nov 2021 – From PCR London Valves
Real-world outcomes for tricuspid edge-to-edge repair, predictors of heart failure hospitalisation and its impact on clinical outcomes, one-year outcomes after TMVI... View part of the Late-Breaking Trials presented during PCR London Valves 2021.
Predictability at release means better MR outcomes; PASCAL platform significance in a matched analysis
21 Nov 2021 – From PCR London Valves 2021
Join Peter Lüdike and Philipp Lurz to learn more about about the latest study regarding the predictability of mitral regurgitation reduction using the PASCAL device.
EAPCI: patient initiatives around the world
22 Nov 2021 – From PCR London Valves 2021
In this session, you can find out more about the EAPCI Valve for Life initiative and what progress has been made in selected countries, as well as other collaborative initiatives across the world.
SURTAVI: five-year results from a randomized trial of TAVR vs. SAVR in patients at intermediate surgical risk
07 Nov 2021
Although TAVI is an accepted alternative to surgery in patients with severe aortic stenosis who are at high surgical risk, less is known about long-term comparative outcomes among patients with aortic stenosis who are at intermediate surgical risk. P. Redaelli & M. Pighi review the SURTAVI trial...
Author
Author
World Heart Day 2023: Reducing the burden of cardiovascular disease globally: beyond stents and balloons!
29 Sep 2023
Global burden of Cardiovascular Disease
Cardiovascular disease (CVD) remains the lead cause of mortality for men and women globally. Our world population in 2023 is 8 billion! Of these, around 620 million people are living with heart and circulatory diseases across the world. Each year around 60...
Author
BRIGHT-4 – Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial
07 Nov 2022
Nicola Ryan provides her take on the BRIGHT-4 study, which was presented during AHA 2022 in Chicago, & simultaneously published in the Lancet.
This study was a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 hours post PPCI was superior to unfractionated...
Author
The Lancet Commission to reduce global burden of cardiovascular disease in women by 2030
29 Aug 2021
Vijay Kunadian summarizes the key points of the LBT session of the ESC congress 2021 held on Sunday, 29 August focusing on the Lancet Commission to reduce the global burden of heart disease in women by 2030.
Author
Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions
08 Jan 2025
In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.
Author
